Skip to main navigation

Contact Us
Global
- International
- Canada
- France
- Germany
- Italy
- Japan
- Netherlands
- Spain

About Amicus
- About Amicus
- Chairman’s Welcome
- Leadership
- Belief Statement
- Contact Us
- Message from BIO
Patient Advocacy
- Patient Advocacy
- Disease Information
- Rare Stories
- Patient Advisory Boards
- Corporate Giving
- Resources
- Expanded Access
Programs & Pipeline
- Programs & Pipeline
- Our Pipeline
- Fabry Disease
- Pompe Disease
- Batten Disease
- Additional Preclinical Programs
- Clinical Trials
- Platform Technologies
- Journal Articles
- Publications & Posters
Product
- Product
- Galafold^®
- Amicus Assist™
Responsibility
- Responsibility
- Ethics & Compliance
- Global Medical Affairs
- Corporate Giving
- Healing Beyond Disease
Investors & Media
- Investors & Media
- Investor Relations
- Senior Management Team
- Board of Directors
- Corporate Governance
- Press Releases
- Events & Presentations
- Annual Reports and Proxies
- SEC Filings
- Stock Performance
- Investor FAQs
- Contact Us
- Sign Up for Email Alerts
- Featured Coverage
- Electronic Press Kit
Careers
- Careers
- Overview
- Search

Investors

Press Releases

Press Releases

Year

December 2, 2020

Amicus Therapeutics Appoints Michael A. Kelly to its Board of Directors

December 1, 2020

Amicus Therapeutics Initiates Rolling Biologic License Application to the U.S. Food and Drug Administration for AT-GAA in Late-Onset Pompe Disease

November 23, 2020

Amicus Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Conference

November 5, 2020

Amicus Therapeutics Announces Third Quarter 2020 Financial Results and Corporate Updates

November 2, 2020

Amicus Therapeutics to Present at the Credit Suisse 29th Annual Virtual Healthcare Conference

October 22, 2020

Amicus Therapeutics to Announce Third Quarter 2020 Financial Results on November 5, 2020

October 12, 2020

Amicus Therapeutics Announces Additional Positive Interim Clinical Data for CLN6 Batten Disease Gene Therapy at 49th Annual Meeting of the Child Neurology Society

September 24, 2020

Amicus Therapeutics Receives European Medicines Agency PRIME Designation for CLN6 Batten Disease Gene Therapy

September 3, 2020

Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2020

August 10, 2020

Amicus Therapeutics Announces Second Quarter 2020 Financial Results and Corporate Updates

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

About Amicus

Patient Advocacy

Programs & Pipeline

Product
- Overview
- Amicus Assist™

Responsibility

Investors & Media

Careers
- Overview
- Search

Social Media
- Twitter
- YouTube
- LinkedIn

Copyright © 2020 Amicus Therapeutics. All rights reserved. NP-AT-ALL-00011119

Cookies Statement
Terms of Use
Privacy Notice
Privacy Shield Policy

The site you are about to enter is intended for US healthcare professionals.

Please confirm you are a US healthcare professional.

I am a US healthcare professional I am not a US healthcare professional